The Impact of Patient Public Involvement on Clinical Research
|
|
- Godwin Francis
- 5 years ago
- Views:
Transcription
1 The Impact of Patient Public Involvement on Clinical Research Dr Sue Pavitt Reader in Applied Health Sciences Leeds Institute of Health Sciences University of Leeds
2 Overview Aim To understand how Patient Public Involvement (PPI ) can impact of clinical research Objectives Introduction to Patient Public Involvement (PPI) PPI impact on clinical trials - case studies Study Design Study literature & informed consent Study logistics Recruitment & Retention
3 Who are the PP in PPI? By Public and Patient we mean: Patients / potential patients People who use health and social services Carers (unpaid) Family members Disabled persons Members of the public who have been targeted by a specific research grant programme Organisations that represent patients and public s views Individuals/groups that are affected by health or clinical issues
4 What is the I in PPI? An active partnership between the public and researchers in the research process Research to, about or for the public Research with or by the public RAISES PATIENT PUBLIC PERCEPTION OF CLINICAL TRIALS
5 Benefits of PPI User involvement in clinical research is valuable and ensures: vdifferent perspectives heard vresearch priorities identified by medics are also important and relevant to users voutcomes important to users are measured vimproved research design vimproved trial logistics vaccess to patients - via peer networks vaccess hard-to-reach patient groups veffective dissemination Improved research that addresses: patient needs, achieves recruitment & retention and delivers to target
6 PPI in Designing a Trial Questions asked in Designing a Trial 4 th Question what do patients think? qare we asking the right question to improve the health and quality of life for patients?
7 Case Study 1: Getting the right research question(s) q Example from Oral Cancer Oncologist focus 5-year survival at any cost Patient focus quality of life issues function & disfigurement v Trial designed to address future patients needs - providing complete impact of treatment on survival and quality of life v Improved Recruitment & Retention - patient sees trial as important
8 Case Study 2- SWITCH PPI Impact on Trial Design: Ethics, safety and cost implications SWITCH RCT N=870 Patients with Rheumatoid Arthritis who have failed a TNF antagonist Biologic Therapy N=290 Alternative Mechanism TNF N=290 Abatacept Schedule 14 Tx; IV 90 mins N=290 Rituximab-Comparator Schedule 2 Tx;IV 405 mins Infliximab Schedule 8 Tx IV 225 mins Adalimumab Schedule 26 Tx SC 30 mins v Funders suggested the SWITCH trial Tx should be blinded. PPI representatives argued: v Unethical & safety concerns - drug treatment schedule different for Tx arms v 71 treatments/patient (average 4.5 fold higher than non-blinded) v 78.5 hours of treatment/patient (average 4.3 fold higher than non-blinded) v Trial costs would be significantly higher v Saved 2.5m in Tx delivery costs alone Etanercept Schedule 52 Tx SC 30 mins Certolizumab Schedule 26 Tx SC 30 mins v Lose pragmatic design - results may not be transferable to everyday practice
9 SWITCH PPI impact on trial design Patient friendly design & value for money PPI improved trial design and retained a more ethical, safer and pragmatic drug trial ØEquivalence design provides more drug options to patients ØParticipant friendly trial keeps refusals to a minimum ØMinimises Tx appointments from weekly to actual recommended Tx schedule for each drug Ø Improved fundng success reduced budget by several million ØImproved patient safety fewer intravenous infusions
10 Case Study 3: Lessons learnt from the ProtecT Trial: impact on trial literature ProtecT Prostate testing for cancer treatment v Recruiters found it difficult to explain the uncertainty about treatment and did not present options equally v Non-treatment arm described as watchful waiting v Patients interpreted as if clinicians would watch while I die v PPI changed descriptor to active monitoring v Recruitment rates increased from 40% to 70%
11 Case Study 4: PPI Impact on Trial Literature IMPROVDENT An RCT to improve the fit of dentures by testing two dental impression materials Trial Literature Reviewed Recommendations to make the Patient Information Leaflets more understandable Improved Trial Operations Trial is explained better results in improved uptake Timely ethics approval Early attainment of recruitment to schedule
12 Case Study 4: PPI Impact on Trial operations / logistics Trial Operational input Appointments available largely between 10am - 3pm Accommodates travel to appointments on Senior Citizen Bus Pass Improved Trial Operations Trial is user friendly Participants less inconvenienced Few cancelled appointments Recruitment to schedule
13 Better designed trials improve Recruitment & Retention RECRUITMENT 2/3rds of trials fail to reach target and require expensive extensions Expensive extensions or Underpowered trials RETENTION 1/3 rd enrolees drop out AWARENESS ADDITIONAL SUPPORT
14 The Future - PPI Integral to Clinical Trial Design & Recruitment Strategy q Trial designed to take account of patients needs q Trial operations / logistics made patient friendly q Trial literature simplified Ensuring informed consent Improved Recruitment & Retention Patient Benefit Improved Health Improved Delivery of Trials & Evidencebased Medicine
15 Any Questions? Dr Sue Pavitt Leeds Institute of Health Sciences +44 (0)
Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta480
Tofacitinib for moderate to severeere rheumatoid arthritis Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta480 NICE 2018. All rights reserved. Subject to Notice of rights
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
DERBYSHIRE JOINT AREA PRERIBING COMMITTEE (JAPC) Derbyshire commissioning guidance on biologic drugs f the treatment of Rheumatoid arthritis with methotrexate This algithm is a tool to aid the implementation
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationNational Institute for Health and Clinical Excellence SCOPE. Rheumatoid arthritis: the management and treatment of rheumatoid arthritis in adults
National Institute for Health and Clinical Excellence 1 Guideline title SCOPE Rheumatoid arthritis: the management and treatment of rheumatoid arthritis in adults 1.1 Short title Rheumatoid arthritis 2
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationOrencia (abatacept) for Rheumatoid Arthritis. Media backgrounder
Orencia (abatacept) for Rheumatoid Arthritis Media backgrounder What is Orencia (abatacept)? Orencia (abatacept) is the first biologic agent to be available in both an intravenous (IV) and a self-injectable,
More informationehealth and Data Analytics Dementia Pathfinder Programme Dementia Analytics Research User Group (DARUG) PPI Steering Group
ehealth and Data Analytics Dementia Pathfinder Programme Dementia Analytics Research User Group (DARUG) PPI Steering Group Role Description & Terms of Reference August 2018 Role Description Project overview
More information1 Executive summary. Background
1 Executive summary Background Rheumatoid Arthritis (RA) is the most common inflammatory polyarthropathy in the UK affecting between.5% and 1% of the population. The mainstay of RA treatment interventions
More informationScottish Medicines Consortium
Scottish Medicines Consortium abatacept, 250mg powder for concentrate for solution (Orencia ) No. (400/07) Bristol Myers Squibb Pharmaceuticals Ltd 10 August 2007 The Scottish Medicines Consortium has
More informationInnovative Income: Diversifying John Hinton Move On MOVE ON - UNLOCKING YOUR POTENTIAL
Innovative Income: Diversifying John Hinton Move On About Move On To unlock the potential of vulnerable young people and those affected by homelessness in order to improve their lives. Established in 1997.
More informationPatient Participation Groups
Patient Participation Groups What you need to know about GP Online Services August 2018 Dear Patient Participation Group member First of all, thank you for taking the time to read through this document.
More informationPatient and public involvement. Guidance for researchers
Patient and public involvement Guidance for researchers Contents What is patient and public involvement and why is it important? 3 Benefits of patient and public involvement for researchers 4 Levels of
More informationCost-effectiveness of apremilast (Otezla )
Cost-effectiveness of apremilast (Otezla ) alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs) for the treatment of active psoriatic arthritis in adult patients who have had an
More informationPrioritising uncertainties assembled in UK DUETs, for additional research. NHS Evidence provided by NICE
Prioritising uncertainties assembled in UK DUETs, for additional research NHS Evidence provided by NICE James Lind Alliance Tackling treatment uncertainties together Patients and Clinicians James Lind,
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationFor Rheumatoid Arthritis
For Rheumatoid Arthritis APRIL 2017 NOTICE: On April 14, 2017 the FDA issued a complete response letter for baricitinib indicating that the FDA is unable to approve the application in its current form
More informationSteps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS
Moderate to Severe Rheumatoid Arthritis (RA) 3 Steps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS INDICATION/USAGE Adult Rheumatoid Arthritis (RA): ORENCIA (abatacept) is a prescription
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationGet an Insurance Benefits Review for ORENCIA (abatacept)
Get an Insurance Benefits Review for ORENCIA (abatacept) If you and your doctor decide that ORENCIA is right for you, you can call 1-800-ORENCIA (1-800-673-6242) to do an Insurance Benefits Review. Our
More informationCommissioning for Better Outcomes in COPD
Commissioning for Better Outcomes in COPD Dr Matt Kearney Primary Care & Public Health Advisor Respiratory Programme, Department of Health General Practitioner, Runcorn November 2011 What are the Commissioning
More informationInvolvement of consumers in studies run by the Medical Research Council Clinical Trials Unit (MRC CTU): Results of a survey
Involvement of consumers in studies run by the Medical Research Council Clinical Trials Unit (MRC CTU): Results of a survey Claire Vale, Lindsay Thompson, Claire Murphy, Silvia Forcat & Bec Hanley, MRC
More informationNIHR Leeds Clinical Research Facility Patient and Public Involvement Strategy
NIHR Leeds Clinical Research Facility Patient and Public Involvement Strategy 2015-17 Leeds Teaching Hospitals NHS Trust Beckett Street, Leeds LS9 7TF http://www.leedsth.nhs.uk/research LCRF PPI Strategy
More informationRichard Watson, Chief Transformation Officer. Dr P Holloway, GP Clinical Lead for Cancer Lisa Parrish, Senior Transformation Lead
GOVERNING BODY Agenda Item No. 08 Reference No. IESCCG 18-02 Date. 23 January 2018 Title Lead Chief Officer Author(s) Purpose Cancer Services Update Richard Watson, Chief Transformation Officer Dr P Holloway,
More informationINTERNATIONAL STILLBIRTH ALLIANCE STRATEGIC DIRECTIONS AND GOALS FOR
INTERNATIONAL STILLBIRTH ALLIANCE STRATEGIC DIRECTIONS AND GOALS FOR 2009-2013 This document outlines the mission, vision, guiding principles and strategic goals for ISA over the next 5 years. For more
More informationMacmillan Cancer Improvement Partnership (MCIP) An introduction
Macmillan Cancer Improvement Partnership (MCIP) An introduction What is MCIP? The Macmillan Cancer Improvement Partnership in Manchester brings together the city s cancer care services and their funders
More informationDRAFT MINUTES OF AWP Mental Health Partnership Trust Held on 11 September 2013 at Jenner House, Langley Park, Chippenham. SN15 1GG
DRAFT MINUTES OF AWP Mental Health Partnership Trust Held on 11 September 2013 at Jenner House, Langley Park, Chippenham. SN15 1GG These Minutes are presented for Approval Board members present Tony Gallagher
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION TOFACITINIB (Xeljanz Pfizer Canada Inc.) Indication: Rheumatoid Arthritis Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that tofacitinib be listed, in combination
More informationAchieve. Salford Young People s Service. Salford Recovery
Achieve Salford Young People s Service Achieve Salford Recovery Services Achieve SAlford recovery ServiceS Achieve Salford Recovery Services brings together people from a range of organisations, backgrounds
More informationBORDERS ALCOHOL AND DRUGS PARTNERSHIP (ADP) DELIVERY PLAN UPDATE FOR CPP STRATEGIC BOARD. Fiona Doig. 1 September 2016
BORDERS ALCOHOL AND DRUGS PARTNERSHIP (ADP) DELIVERY PLAN 2015-2018 UPDATE FOR CPP STRATEGIC BOARD Fiona Doig 1 September 2016 CONTENTS Contents 1 troduction... 3 2 ADP Strategy Priorities for 2015-16...4
More informationin North East Lincolnshire Care Trust Plus Implementation Plan Executive Summary
North East Lincolnshire Care Trust Plus Living Well with Dementia in North East Lincolnshire Implementation Plan 2011-2014 Executive Summary Our vision is for all Individuals with Dementia and their carers
More informationProfessor Peter Robinson Professor in Dental Public Health University of Sheffield. Reader in Applied Health Research, University of Leeds
Improving the organisation and delivery of dental health care to patients innovation in the commissioning of primary dental care service delivery and organisation Dr Sue Pavitt Reader in Applied Health
More informationStrategy Registered Charity
Strategy 2015-2025 Registered Charity 516898 Why do we exist? Yorkshire has the third worst cancer incidence rates in England. 11 of 13 local authorities in the county have outcomes below the national
More informationIntegrated Diabetes Care in Oxfordshire -patient's perspective. Avril Surridge
Integrated Diabetes Care in Oxfordshire -patient's perspective Avril Surridge Today How does diabetes care in Oxfordshire look like from a patient s perspective? Good things What could be improved? National
More informationDCP Newsletter. Welcome. Issue 1 June Key Dates. National Men s Health Week June 2018
DCP Newsletter Issue 1 June 2018 Welcome Hello and a warm welcome to all of our readers of this first edition of the Dorset Cancer Partnership (DCP) newsletter. Each edition of this newsletter will provide
More informationSimply, participation means individual s involvement in decisions that affect them.
Simply, participation means individual s involvement in decisions that affect them. NHS England guidance on participation sets out two types of participation in healthcare: 1) people s involvement in decisions
More informationThe Hospital for Sick Children Technology Assessment at SickKids (TASK)
The Hospital for Sick Children Technology Assessment at SickKids (TASK) THE USE OF BIOLOGIC RESPONSE MODIFIERS IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS Report No. 2010-01 Date: January 11,
More informationCORPORATE REPORT Communication strategy
CORPORATE REPORT Communication Strategy 2014-17 1 Introduction This strategy sets out the Commission s goals and objectives in relation to its communication activities for the next three years. It has
More informationinfliximab, 100mg, powder for concentrate for solution for infusion (Inflectra ) SMC No. (1007/14) Hospira UK Ltd.
infliximab, 100mg, powder for concentrate for solution for infusion (Inflectra ) SMC No. (1007/14) Hospira UK Ltd. 07 November 2014 (Issued 06 March 2015) The Scottish Medicines Consortium (SMC) has completed
More informationEvaluation of the Health and Social Care Professionals Programme Interim report. Prostate Cancer UK
Evaluation of the Health and Social Care Professionals Programme Interim report Prostate Cancer UK July 2014 Contents Executive summary... 2 Summary of the research... 2 Main findings... 2 Lessons learned...
More information(minutes for web publishing)
Rheumatology Subcommittee of the Pharmacology and Therapeutics Advisory Committee (PTAC) Meeting held on 17 October 2017 (minutes for web publishing) Rheumatology Subcommittee minutes are published in
More informationKEEP UP THE FIGHT WITH. Little Victories
FOR MODERATE TO SEVERE RHEUMATOID ARTHRITIS (RA) KEEP UP THE FIGHT WITH Little Victories Small improvements in your daily activities may be a sign that ORENCIA (abatacept) is working for you. Use this
More informationTechnology appraisal guidance Published: 22 February 2012 nice.org.uk/guidance/ta247
Tocilizumab for the treatment of rheumatoid arthritis Technology appraisal guidance Published: 22 February 2012 nice.org.uk/guidance/ta247 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationCenter for Evidence-based Policy
P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N
More informationMental Health Matters
www.stpatricks.ie Mental Health Matters 2013 2018 Empowering Recovery st patrick s mental health services Empowering recovery St. Patrick s Mental Health Services Mental Health Matters 2013 2018 strategy
More informationTechnology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340
Ustekinumab for treating active psoriatic arthritis Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationProgress in improving cancer services and outcomes in England. Report. Department of Health, NHS England and Public Health England
Report by the Comptroller and Auditor General Department of Health, NHS England and Public Health England Progress in improving cancer services and outcomes in England HC 949 SESSION 2014-15 15 JANUARY
More informationDuring the Health Issues Centre conducted a project for the Ministerial Taskforce for Cancer. This project aimed to:
Consumer Participation Plan 2015-2016 Introduction Barwon South Western Regional Integrated Cancer Service (BSWRICS) is committed to improving the experiences and outcomes of those affected by cancer in
More informationStaying Strong - but for how long? A follow up to the Staying Strong Guide produced by The National Forum of People with Learning Difficulties.
Staying Strong - but for how long? A follow up to the Staying Strong Guide produced by The National Forum of People with Learning Difficulties. Staying Strong but for how long? This report has been written
More informationCertolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line
Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line August 2011 This technology summary is based on information available at the time of research and a limited
More informationWE VE MADE FIXED FULL-ARCH RESTORATIONS A SNAP. NO SCREWS. NO CEMENT. NO COMPROMISES.
WE VE MADE FIXED FULL-ARCH RESTORATIONS A SNAP. NO SCREWS. NO CEMENT. NO COMPROMISES. LOCATOR F-Tx A NEW WAY TO THINK ABOUT FIXED FULL-ARCH RESTORATIONS. LOCATOR F-Tx IS A SIMPLIFIED, TIME SAVING SOLUTION
More information2 WHO 1 Who do you need to involve? a specific condition, service or treatment
PATIENT AND PUBLIC ENGAGEMENT PLANNING TEMPLATE Instructions: Patient engagement is about meaningful engagement of patients/public in the research process (not just as subjects of research). This template
More informationThe role of cancer networks in the new NHS
The role of cancer networks in the new NHS October 2012 UK Office, 89 Albert Embankment, London SE1 7UQ Questions about cancer? Call the Macmillan Support Line free on 0808 808 00 00 or visit macmillan.org.uk
More informationORENCIA (oh-ren-see-ah) (abatacept)
17.7 FDA-Approved Patient Labeling PATIENT INFORMATION ORENCIA (oh-ren-see-ah) (abatacept) Read this Patient Information before you start receiving ORENCIA and each time before you are scheduled to receive
More information2017 Blue Cross and Blue Shield of Louisiana
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationOver the summer Salford Together held a comprehensive engagement exercise with the people of Salford.
Final report December 2017 The Big Health and Social Care Conversation - Final Report Executive summary Over the summer Salford Together held a comprehensive engagement exercise with the people of Salford.
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationThank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationA PATIENT AND PUBLIC INVOLVEMENT STRATEGY RESEARCH DESIGN SERVICE NORTH WEST. November 2011 Version 2.0
A PATIENT AND PUBLIC INVOLVEMENT STRATEGY RESEARCH DESIGN SERVICE NORTH WEST November 2011 Version 2.0 Page 1 of 8 Our aim The overall aim of the NIHR Research Design Service North West (NIHR RDS NW) in
More informationCertolizumab pegol (Cimzia) for chronic plaque psoriasis in adults
NIHR Innovation Observatory Evidence Briefing: April 2017 Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults NIHRIO (HSRIC) ID: 2406 NICE ID: 9112 LAY SUMMARY Plaque psoriasis is the most
More informationNational Institute for Health and Clinical Excellence Level 1A, City Tower Piccadilly Plaza Manchester M1 4BD
xxxxx xxxxxx xxxxxx xxxxxxx - xxxxxxxxx x National Institute for Health and Clinical Excellence Level 1A, City Tower Piccadilly Plaza Manchester M1 4BD Dear xxxxx, 1st September 2011 Comments on the August
More informationAdherence to Non-Infused Biologic Medications Used to Treat Rheumatoid Arthritis (PDC-RA)
Adherence to Non-Infused Biologic Medications Used to Treat Rheumatoid Arthritis (PDC-RA) Description The percentage of patients 18 years and older with rheumatoid arthritis (RA) who met the Proportion
More informationPathfinder Case Study: Engaging with parent carers Case study text (minus headings, contact information etc) should run to a maximum of 3 sides of A4
Pathfinder Case Study: Engaging with parent carers Case study text (minus headings, contact information etc) should run to a maximum of 3 sides of A4 Pathfinder Name: Local Authority(ies) and health authorities
More informationHighfield Centre & Rainbow Children's Centre
This is a summary of three evaluations commissioned by SureStart Keighley in 2005. We wanted to find out what local people who use our services have experienced and how they would like to see them develop
More informationInvitation to Tender
Invitation to Tender Contact: Project: Jacob Diggle, Research and Evaluation Officer j.diggle@mind.org.uk Peer Support Programme Date: January 2015 Brief description: Mind has recently secured 3.2 million
More informationVolunteering in NHSScotland Developing and Sustaining Volunteering in NHSScotland
NG11-07 ing in NHSScotland Developing and Sustaining ing in NHSScotland Outcomes The National Group for ing in NHS Scotland agreed the outcomes below which formed the basis of the programme to develop
More informationRheumatoid arthritis 2010: Treatment and monitoring
October 12, 2010 By Yusuf Yazici, MD [1] The significant changes in the way rheumatoid arthritis has been managed include earlier, more aggressive treatment with combination therapy. Significant changes
More information1. Comparative effectiveness of vedolizumab
Cost-effectiveness of vedolizumab (Entyvio ) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were
More informationPatient and Public Involvement in JPND Research
Patient and Public Involvement in JPND Research A user-friendly guide for applicants to JPND Calls for proposals January 5 2015 Created in conjunction with DenDRoN, United Kingdom Purpose The purpose of
More informationCo-operative Clinical Trials in Cancer the need for increased capacity
Co-operative Clinical Trials in Cancer the need for increased capacity The Executive Summary, Recommendations and Budget from the report by Oceania Health Consulting January 2002 Executive summary In the
More informationEffective Health Care Program
Comparative Effectiveness Review Number 55 Effective Health Care Program Drug Therapy for Rheumatoid Arthritis in Adults: An Update Executive Summary Background Rheumatoid arthritis (RA), which affects
More informationModel Tender Document
Model Tender Document This document is a guide to essential components in designing a tender for services for survivors of violence against women and girls (VAWG) and is intended to be read in conjunction
More informationFIXED-HYBRID EMERGENCY! Why Redo When You Can Rescue?
FIXED-HYBRID EMERGENCY! Why Redo When You Can Rescue? FIXED-HYBRID FAILURES HAPPEN When a failing implant needs to be replaced in a fixed-hybrid case, it often leads to a prosthesis emergency. Replacing
More informationREADY FOR THE ADVENTURE? DEPUTY UK YOUTH COMMISSIONER CANDIDATE PACK
READY FOR THE ADVENTURE? DEPUTY UK YOUTH COMMISSIONER CANDIDATE PACK ABOUT US Overview of Scouting We are the UK s biggest mixed youth organisation. We change lives by offering 6 to 25 year olds fun and
More informationCRN Wessex Patient Research Experience Survey 2017/18 Report
Clinical Research Network Wessex CRN Wessex Patient Research Experience Survey 2017/18 Report Authors names & job titles Main issues/executive Summary Kim Appleby, communications lead, CRN Wessex and Graham
More informationInvitation to Tender
Invitation to Tender Contact: Project: Jacob Diggle, Senior Research and Evaluation Officer j.diggle@mind.org.uk Your Experience in Mind : Service User Survey Date: February 2015 Brief description: Mind
More informationINTERNAL QUESTIONS AND ANSWERS DRAFT
WHO CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION Background: INTERNAL QUESTIONS AND ANSWERS DRAFT At the end of 2012, 9.7 million people were receiving
More informationBarnet Scrutiny Committee report 13 th October Barnet Sexual Health Strategy Dr Andrew Howe, Director of Public Health
Barnet Scrutiny Committee report 13 th October 2015 Title Report of Wards Status Urgent Key Enclosures Officer Contact Details Barnet Sexual Health Strategy 2015-2020 Dr Andrew Howe, Director of Public
More informationTechnology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta466
Baricitinib for moderate to severeere rheumatoid arthritis Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta466 NICE 2017. All rights reserved. Subject to Notice of rights
More informationORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira ( adalimumab
ORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents ORENCIA demonstrated comparable
More informationOpportunities to become involved
Opportunities to become involved Belfast Trust aims to improve services through meaningful involvement with patients, service users, family cares and communities. In addition to being involved in your
More informationAbout the Ageing Better programme
Ageing Better Crossgates Lunch Club, Leeds About the Ageing Better programme Ageing Better is a National Lottery funded programme set up by the Big Lottery Fund, the largest funder of community activity
More informationDementia in England. Dr Charles Alessi Senior Advisor on Dementia, Public Health England
Dementia in England Dr Charles Alessi Senior Advisor on Dementia, Public Health England The health and care system in England National Health Service (NHS) World s largest publicly funded health service
More informationNHS England Impact Analysis of implementing NHS Diabetes Prevention Programme, 2016 to 2021
NHS England Impact Analysis of implementing NHS Diabetes Prevention Programme, 2016 to 2021 1. Purpose The purpose of this document is to describe both the estimated resource implications to NHS England
More informationKent Joint Commissioning Action Plan For Adults with Autism and or ADHD (2017 / 2021)
Easy Read Kent Joint Commissioning Action Plan For Adults with Autism and or ADHD (2017 / 2021) Action Plan The plan was developed to address the needs identified from the Kent Autism Strategy and Joint
More informationWest Yorkshire & Harrogate Health and Care Partnership
West Yorkshire & Harrogate Health and Care Partnership Engagement mapping on the communication needs for people with a sensory impairment November 2017 1.0 Introduction The purpose of the report is to
More informationPrevention and wellbeing. Amanda McGlennon Richmond CCG Debbie Davies East London NHS Foundation Trust Val Farmer Richmond Borough Mind
Prevention and wellbeing Amanda McGlennon Richmond CCG Debbie Davies East London NHS Foundation Trust Val Farmer Richmond Borough Mind Prevention and wellbeing All services should be delivered to support
More informationAUTISM STRATEGY FOR ADULTS IN BIRMINGHAM
CONSULTATION DOCUMENT AUTISM STRATEGY FOR ADULTS IN BIRMINGHAM 2013 2016 HELPING ADULTS WITH AUTISM TO ACHIEVE FULFILLING AND REWARDING LIVES RAISING AWARENESS TO INFORM, IMPLEMENT AND IMPROVE Strategy
More informationHealth and Social Care Alliance Scotland: People at the Centre
Health and Social Care Alliance Scotland: People at the Centre Nancy Greig, Network Development Officer, Health and Social Care Alliance Scotland (the ALLIANCE) The Long Term Conditions Alliance Scotland
More informationNational Cancer Programme. Work Plan 2015/16
National Cancer Programme Work Plan 2015/16 Citation: Ministry of Health. 2015. National Cancer Programme: Work plan 2015/16. Wellington: Ministry of Health. Published in October 2015 by the Ministry of
More informationThe response to the Committee request for additional analyses in section 1.4, MSD follows:
MSD Hertford Road Hoddesdon, Hertfordshire EN11 9BU, UK Telephone +44 (0)1992 452644 Facsimile +44 (0)1992 468175 1 Kate Moore Technology Appraisals Project Manager National Institute for Health and Clinical
More informationShaping the services you use
Shaping the services you use fsdc would like to thank Action for Sick Children Scotland for their help in producing this guide. COVER IMAGE CREDIT: flickr.com/stephanski A guide to parent participation
More informationRecommendation 2: Voluntary groups should be supported to build their capacity to promote mental health among their client groups.
Submission to the independent review group examining the role of voluntary organisations in the operation of health and personal social services in Ireland May 2018 Introduction Mental Health Reform (MHR)
More informationEmotional Wellbeing & Mental Health Fund
Emotional Wellbeing & Mental Health Fund Grants of up to 10k for 2018/19 & 50k/yr for 2018-21 Closing Date 27.08.18 Supported by Emotional Wellbeing & Mental Health Fund Guidance Notes Before you start
More informationThe Leeds Teaching Hospitals NHS Trust. Positive Patient and Public Involvement (PPI) in Research at Leeds
n The Leeds Teaching Hospitals NHS Trust Positive Patient and Public Involvement (PPI) in Research at Leeds Acknowledgements We would like to thank the following PPI members for their contributions in
More informationBy: For: Division responsible for document: Key words: Name and job title of document author: Name and job title of document author s Line Manager:
For Use in: By: For: Guidelines for the Management of Interruption of Biologic Therapies for Division responsible for document: Key words: Name and job title of document author: Name and job title of document
More informationJob Description & Person Specification Palliative Care Research Network Project Manager
Job Description & Person Specification Palliative Care Research Network Project Manager Job Title: Project Manager (0.5WTE Specified Purpose Contract) Accountable to: Head of Institute of All Ireland Institute
More informationSummary of Risk Minimization Measures
Table 6.1.4-1: Summary of Risk Minimization Measures Safety Concern Vaccination Hepatic and renal impairment Combination therapy Elderly Routine Risk Minimization Measures Specific subsection on vaccination
More informationDementia 2014: Opportunity for change England summary
Dementia 2014: Opportunity for change England summary Dementia 2014: Opportunity for change England summary 2 Dementia 2014: Opportunity for change provides a comprehensive summary of the key areas affecting
More information